JP2009544582A - γδＴ細胞活性化物質を使用して治療用抗体の効率を増大させる方法および組成物 - Google Patents

γδＴ細胞活性化物質を使用して治療用抗体の効率を増大させる方法および組成物 Download PDF

Info

Publication number
JP2009544582A
JP2009544582A JP2009518903A JP2009518903A JP2009544582A JP 2009544582 A JP2009544582 A JP 2009544582A JP 2009518903 A JP2009518903 A JP 2009518903A JP 2009518903 A JP2009518903 A JP 2009518903A JP 2009544582 A JP2009544582 A JP 2009544582A
Authority
JP
Japan
Prior art keywords
group
cell
cell activator
cells
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009518903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544582A5 (enExample
Inventor
ジャン−ジャック・フルニエ
ジュリー・ジェルトネ
エレーヌ・シカル
ギィ・ロラン
クリスティーヌ・ブゾンブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Innate Pharma SA
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale, Innate Pharma SA filed Critical Institut National de la Santé et de la Recherche Médicale
Publication of JP2009544582A publication Critical patent/JP2009544582A/ja
Publication of JP2009544582A5 publication Critical patent/JP2009544582A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009518903A 2006-07-13 2007-07-12 γδＴ細胞活性化物質を使用して治療用抗体の効率を増大させる方法および組成物 Pending JP2009544582A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06291146A EP1878440A1 (en) 2006-07-13 2006-07-13 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
US92420807P 2007-05-03 2007-05-03
PCT/EP2007/057217 WO2008006895A2 (en) 2006-07-13 2007-07-12 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators

Publications (2)

Publication Number Publication Date
JP2009544582A true JP2009544582A (ja) 2009-12-17
JP2009544582A5 JP2009544582A5 (enExample) 2010-08-26

Family

ID=37708304

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009518903A Pending JP2009544582A (ja) 2006-07-13 2007-07-12 γδＴ細胞活性化物質を使用して治療用抗体の効率を増大させる方法および組成物

Country Status (6)

Country Link
US (1) US20090304688A1 (enExample)
EP (2) EP1878440A1 (enExample)
JP (1) JP2009544582A (enExample)
AU (1) AU2007274295A1 (enExample)
CA (1) CA2658222A1 (enExample)
WO (1) WO2008006895A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016021720A1 (ja) * 2014-08-07 2016-02-11 学校法人兵庫医科大学 Ｉｌ－１８と分子標的抗体とを併用する癌治療薬
JP2022513328A (ja) * 2018-09-27 2022-02-07 フォスフォガム， インコーポレイテッド 同種異系のガンマ／デルタｔ細胞の増殖および使用のための方法および組成物

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008146167A2 (en) * 2007-06-01 2008-12-04 Innate Pharma S.A. Improved methods of using phosphoantigens together with interleukin-2 for the treatment of cancer
US8735624B2 (en) 2008-09-10 2014-05-27 Innate Pharma Polymorphic form of CHDMAPP, method of preparation thereof, and pharmaceutical composition comprising same
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
MX386714B (es) 2015-01-27 2025-03-11 Lava Therapeutics N V Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d).
US11980663B2 (en) 2015-07-08 2024-05-14 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
IL297238B2 (en) 2016-01-15 2024-08-01 American Gene Tech Int Inc Methods and preparations for gamma-delta T-cell activation
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
WO2017213697A1 (en) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
CA3028982A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
WO2018017882A1 (en) 2016-07-21 2018-01-25 American Gene Technologies International Inc. Viral vectors for treating parkinson's disease
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
US12559769B2 (en) 2017-06-16 2026-02-24 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
JP7457007B2 (ja) 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用ＣＤ１ｄ免疫グロブリン
EP3876952A4 (en) 2018-11-05 2022-08-24 American Gene Technologies International Inc. VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA
CN109529050A (zh) * 2018-12-07 2019-03-29 广州市妇女儿童医疗中心 Vγ9δ2T细胞、治疗肺癌的药物ZOL和hMSH2协同作用的应用
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
CA3211627A1 (en) * 2021-03-11 2022-09-15 Stanley Hersh Appel Methods and compositions for treatment of disease
CN117264904A (zh) * 2023-09-18 2023-12-22 北京大学第三医院（北京大学第三临床医学院） 一种靶向HER2的γδT细胞及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002523513A (ja) * 1998-09-01 2002-07-30 アンスティテュ ナシオナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル ホスホハロヒドリン、これらの製造方法、及び使用
WO2005054258A2 (en) * 2003-12-02 2005-06-16 Innate Pharma New class of gamma delta t cells activators and use thereof
WO2005067635A2 (en) * 2004-01-06 2005-07-28 Hava Corp. Telephone with automatic switching between cellular and voip networks

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639653A (en) 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
FR2715660A1 (fr) 1994-01-28 1995-08-04 Centre Nat Rech Scient Composés organo-phosphorés activateurs des lymphocytes Tgammadelta, procédé pour préparer et/ou isoler et/ou caractériser ces composés, compositions et utilisations pharmaceutiques.
ATE419008T1 (de) * 2004-04-26 2009-01-15 Innate Pharma Adjuvante zusammensetzung und anwendungsverfahren dafür
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002523513A (ja) * 1998-09-01 2002-07-30 アンスティテュ ナシオナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル ホスホハロヒドリン、これらの製造方法、及び使用
WO2005054258A2 (en) * 2003-12-02 2005-06-16 Innate Pharma New class of gamma delta t cells activators and use thereof
WO2005067635A2 (en) * 2004-01-06 2005-07-28 Hava Corp. Telephone with automatic switching between cellular and voip networks

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5010002853; ＬＩＭ　ＳＥＡＨ　Ｈ: ＢＬＯＯＤ Ｖ１０４　Ｎ１１, 20041116, Ａｂｓｔｒａｃｔ　４８９７, Ｗ．Ｂ．　ＳＡＵＮＤＥＲＳ　ＣＯＭＰＡＮＹ *
JPN5010002854; ＣＡＭＰＢＥＬＬ　Ｐ: ＢＬＯＯＤ　ＲＥＶＩＥＷＳ Ｖ１７　Ｎ３, 200309, Ｐ１４３-１５２, ＣＨＵＲＣＨＩＬＬ　ＬＩＶＩＮＧＳＴＯＮＥ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016021720A1 (ja) * 2014-08-07 2016-02-11 学校法人兵庫医科大学 Ｉｌ－１８と分子標的抗体とを併用する癌治療薬
US11219672B2 (en) 2014-08-07 2022-01-11 Haruki Okamura Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
JP2022513328A (ja) * 2018-09-27 2022-02-07 フォスフォガム， インコーポレイテッド 同種異系のガンマ／デルタｔ細胞の増殖および使用のための方法および組成物

Also Published As

Publication number Publication date
EP1878440A1 (en) 2008-01-16
CA2658222A1 (en) 2008-01-17
AU2007274295A1 (en) 2008-01-17
WO2008006895A3 (en) 2008-03-27
US20090304688A1 (en) 2009-12-10
EP2040750A2 (en) 2009-04-01
WO2008006895A2 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
WO2008006895A2 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators
JP7860182B2 (ja) 抗体－薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
US12570753B2 (en) Combination therapies with anti CD40 antibodies
JP6816038B2 (ja) 抗ｃｄ３８抗体及びサバイビン阻害剤による血液悪性疾患の併用療法
TWI847979B (zh) 抗cd38 抗體之皮下給藥
EP3506942B1 (en) Carrier-pd-l1 binding agent compositions for treating cancers
JP2021512914A (ja) ナチュラルキラー細胞を活性化する多特異的結合タンパク質を伴うがんの併用療法
US12186304B2 (en) Method for treating cancer by combination of IAP inhibitor and modulator of immune checkpoint molecule
WO2022057942A1 (zh) 一种药物组合及其应用
TW202330038A (zh) 用於治療癌症之ｂ７－ｈ４抗體－藥物結合物
KR20190120783A (ko) Gd2, nkg2d 및 cd16에 결합하는 단백질
EP4476263A2 (en) Pharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16
KR20190120770A (ko) Psma, nkg2d 및 cd16에 결합하는 단백질
WO2025067400A1 (en) Combination of anti-claudin 18.2/anti-4-1bb antibodies and second therapeutic agent in treatment of cancer
US12097199B2 (en) Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies
US20100189681A1 (en) Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer
KR20240099411A (ko) 항-cd38 항체를 사용한 치료에서 코르티코스테로이드 감소
US20250376537A1 (en) Methods of treating cancer using trispecific binding proteins targeting her2-expressing tumors
WO2023073645A1 (en) Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
HK40004904B (en) Carrier-pd-l1 binding agent compositions for treating cancers
HK40004904A (en) Carrier-pd-l1 binding agent compositions for treating cancers
BR112017002729B1 (pt) Terapia de combinação kit para tratar um tumor sólido em um indivíduo, anticorpo ou porção de ligação a antígeno do mesmo, uso e composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100709

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100709

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130507